Data as of:
Price 02-03-26 16:00 ET,
Balance Sheet 2025-09-30,
Income Statement 2025-09-30,
Cash Flow 2025-09-30
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
2-1-2026
Income indicators
Value
Date
EBITDA Positive
Yes
2-1-2026
Net Income Positive
Yes
2-1-2026
Avg CA Burn (Annual %)
-21.92%
2-1-2026
Avg CA Burn (Quarterly %)
28.96%
2-1-2026
Shares Outstanding Changes
Date
Shares Outstanding
Delta
No recent share changes
Short Interest Changes
Latest short interest:
214,240 shares
(19.69% of float)
| Days to cover: 0.15
Date
Short Interest
Delta
Δ %
2026-02-03
214,240 shares
+0
+0.00%
2026-02-02
214,240 shares
+0
+0.00%
2026-01-30
214,240 shares
None
—
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
Date
Volume
Shares Outstanding
Volume / Shares
Price
2026-02-03
2,626,209
1,088,192
241.34%
$2.46
2026-02-02
5,979,233
1,088,192
549.46%
$2.42
2026-01-30
66,693,021
1,088,192
6128.79%
$3.23
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. The company's product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also provides UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. It sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. ENvue Medical, Inc. was incorporated in 2003 and is based in Tyler, Texas.